Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...
The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers ...
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results